pemphigus vulgaris. Pemphigus vulgaris
Conditions
Interventions
Intervention 1: The use of pill type L-carnitine supplement produced by KAREN chemistry company in 1000 mg dose twice a day (morning and evening) for 8 weeks. Intervention 2: The use of pill type plac
Treatment - Drugs
Placebo
The use of pill type L-carnitine supplement produced by KAREN chemistry company in 1000 mg dose twice a day (morning and evening) for 8 weeks
The use of pill type placebo produced by KAREN chemistry company in 1000 mg dose twice a day (morning and evening) for 8 weeks
Sponsors
Vice chancellor for research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 65 Years
Inclusion criteria
Inclusion criteria: INCLUSION CRITERIA: Willingness to cooperate; Affected by pemphigus vulgaris; Minimum one year of pemphigus vulgaris illness; Using Corticosteroid alone or with one of the Methotrexate, Azathioprine and Cellcept drugs; Age between 30 and 65 years old; BMI<35; Lack of Cardiovascular disease, renal, hepatic and inflammatory intestinal diseases; No alcohol consumption; Do not use of any antioxidant supplementation during the last 3 months; No consumption of Cisplatin, Theophylline and Valproate during the past month; Non-smoking and tobacco use (People who have smoked less than five cigarettes daily in previous 6 months); Lack of pregnancy and lactation EXCLUSION CRITERIA: Changing the type of used drug; Find allergy symptoms at any time of the study
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| L-carnitine. Timepoint: Before and 8 weeks after intervention. Method of measurement: Through the serum by ELISA kit.;Osteopentin. Timepoint: Before and 8 weeks after intervention. Method of measurement: Through the serum by ELISA kit.;Total oxidant capacity. Timepoint: Before and 8 weeks after intervention. Method of measurement: Through the serum by ELISA kit.;F2isoprostane. Timepoint: Before and 8 weeks after intervention. Method of measurement: Through the serum by ELISA kit.;Total cholesterol. Timepoint: Before and 8 weeks after intervention. Method of measurement: Through the serum by colorimetric.;Triglycerides. Timepoint: Before and 8 weeks after intervention. Method of measurement: Through the serum by colorimetric.;Low-density lipoprotein. Timepoint: Before and 8 weeks after intervention. Method of measurement: Through the serum by colorimetric.;High-density lipoprotein. Timepoint: Before and 8 weeks after intervention. Method of measurement: Through the serum by colorimetric.;Fasting Blood sugar. Timepoint: Before and 8 weeks after intervention. Method of measurement: Through the serum by colorimetric.;Added at 2017-08-08:bone morphogenic protein 4. Timepoint: Added at 2017-08-08: Before and 8 weeks after intervention. Method of measurement: Added at 2017-08-08: Through the serum by ELISA kit.;Added at 2017-08-08: cystatin c. Timepoint: Added at 2017-08-08: Before and 8 weeks after intervention. Method of measurement: Added at 2017-08-08: Through the serum by ELISA kit.;Added at 2017-10-05: HOMA-IR. Timepoint: Added at 2017-10-05: Before and 8 weeks after intervention. Method of measurement: Added at 2017-10-05: Serum concentration using ELISA kit.;Added at 2017-10-05: SFRP5. Timepoint: Added at 2017-10-05: Before and 8 weeks after intervention. Method of measurement: Added at 2017-10-05: Serum concentration using ELISA kit.;Added at 2017-10-05: Visfatin. Timepoint: Added at 2017-10-05: Before and 8 weeks after intervention. Method of measurement: Added a | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: at the beginning and at the end of the study. Method of measurement: SF-36, GHQ-12, FSS and DLQI questionares.;Added at 2017-10-05: QUICKI. Timepoint: Added at 2017-10-05: Before and 8 weeks after intervention. Method of measurement: Added at 2017-10-05: Serum concentration using ELISA kit.;Added at 2017-10-05: Insulin. Timepoint: Added at 2017-10-05: Before and 8 weeks after intervention. Method of measurement: Added at 2017-10-05: Serum concentration using ELISA kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Hasan Javanbakht
School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences
Outcome results
None listed